514 filings
Page 5 of 26
8-K
crfr9zl
7 Mar 19
ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
7:30am
S-8
36tn977u
29 Nov 18
Registration of securities for employees
4:12pm
S-8
hc1z 98kn
29 Nov 18
Registration of securities for employees
4:11pm
8-K
4vj3j7aw082
31 Oct 18
ArQule Reports Third Quarter 2018 Financial Results
7:30am
CT ORDER
0fm0gypl2177 jf
27 Aug 18
Confidential treatment order
12:00am
8-K
oul g5kce
1 Aug 18
ArQule Reports Second Quarter 2018 Financial Results
7:30am
8-K
jtl0940
13 Jul 18
ArQule Announces Commencement of Proposed Public Offering of Common Stock
5:06pm
424B5
9h1lv
12 Jul 18
Prospectus supplement for primary offering
11:38am
424B5
i431pu om4yax8s8
10 Jul 18
Prospectus supplement for primary offering
5:29pm
EFFECT
3ulrk5abxx0ajxg1xg
31 May 18
Notice of effectiveness
12:15am
CORRESP
8ohiffgr59y7aa7 rm5
29 May 18
Correspondence with SEC
12:00am
UPLOAD
s8v58j4ab5c
24 May 18
Letter from SEC
12:00am
8-K
34plzv
10 May 18
Report of Matters Voted Upon by Stockholders
4:30pm
8-K
7nb3sbixbcbqkiwkjny
7 May 18
Arqule Reports First Quarter 2018 Financial Results
7:30am
8-K
g48q9q1
17 Apr 18
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World excluding Greater China
12:00am
CT ORDER
4ahjpln4r
6 Apr 18
Confidential treatment order
12:00am